安进Amgen（AMGN）2025年第三季度业绩报告「NASDAQ」（英文版）（24页）.pdf

1、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(Nov.4,2025)-Amgen(NASDAQ:AMGN)today announced financial results for the third quarter of 2025.“We delivered strong volume growth this quarter,reflecti

2、ng the demand for our medicines and the impact were having on patients worldwide.With disciplined investment and a pipeline of first-in-class medicines,were focused on expanding access,advancing innovation,and sustaining long-term growth,”said Robert A.Bradway,chairman and chief executive officer.Ke

3、y results include:For the third quarter,total revenues increased 12%to$9.6 billion in comparison to thethird quarter of 2024.Product sales grew 12%,driven by 14%volume growth,partially offset by 4%lower netselling price.Sixteen products delivered at least double-digit sales growth in the third quart

4、er,including Repatha(evolocumab),EVENITY(romosozumab-aqqg),IMDELLTRA(tarlatamab-dlle)/IMDYLLTRA(tarlatamab),TEZSPIRE(tezepelumab-ekko),TEPEZZA(teprotumumab-trbw),BLINCYTO(blinatumomab),UPLIZNA(inebilizumab-cdon),and TAVNEOS(avacopan).GAAP earnings per share(EPS)increased 14%from$5.22 to$5.93,driven

5、by higherrevenues,partially offset by higher operating expenses,including an Otezla intangibleasset impairment charge of$400million recorded during the third quarter of 2025.GAAP operating income increased from$2.0 billion to$2.5 billion,and GAAPoperating margin increased 2.5 percentage points to 27

6、.6%.Non-GAAP EPS increased 1%from$5.58 to$5.64,primarily driven by higher revenues,partially offset by higher operating expenses and a higher effective tax rate.Non-GAAP operating income increased from$4.0 billion to$4.3 billion,and non-GAAPoperating margin decreased 2.5 percentage points to 47.1%.T